Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $21.07 in the prior trading day, Syndax Pharmaceuticals Inc (NASDAQ: SNDX) closed at $20.74, down -1.57%. In other words, the price has decreased by -$1.57 from its previous closing price. On the day, 1.21 million shares were traded. SNDX stock price reached its highest trading level at $21.11 during the session, while it also had its lowest trading level at $20.42.
Ratios:
Our goal is to gain a better understanding of SNDX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.42 and its Current Ratio is at 4.64. In the meantime, Its Debt-to-Equity ratio is 2.99 whereas as Long-Term Debt/Eq ratio is at 2.79.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 08 ’25 when Metzger Michael A sold 157,307 shares for $16.41 per share. The transaction valued at 2,582,021 led to the insider holds 298,661 shares of the business.
MICHAEL METZGER bought 157,307 shares of SNDX for $2,680,511 on Sep 08 ’25. On Aug 18 ’25, another insider, Podlesak Dennis, who serves as the Director of the company, sold 19,200 shares for $15.84 each. As a result, the insider received 304,170 and left with 191,763 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SNDX now has a Market Capitalization of 1802613760 and an Enterprise Value of 1693870720. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.16 while its Price-to-Book (P/B) ratio in mrq is 15.61. Its current Enterprise Value per Revenue stands at 15.218 whereas that against EBITDA is -5.519.
Stock Price History:
The Beta on a monthly basis for SNDX is 0.49, which has changed by 0.49644887 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, SNDX has reached a high of $22.73, while it has fallen to a 52-week low of $8.58. The 50-Day Moving Average of the stock is 16.22%, while the 200-Day Moving Average is calculated to be 50.21%.
Shares Statistics:
The stock has traded on average 2.60M shares per day over the past 3-months and 1303120 shares per day over the last 10 days, according to various share statistics. A total of 86.91M shares are outstanding, with a floating share count of 84.30M. Insiders hold about 3.01% of the company’s shares, while institutions hold 115.77% stake in the company. Shares short for SNDX as of 1765756800 were 22826193 with a Short Ratio of 8.76, compared to 1763078400 on 25622767. Therefore, it implies a Short% of Shares Outstanding of 22826193 and a Short% of Float of 29.62.
Earnings Estimates
The firm’s stock currently is rated by 12.0 analysts. The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.42 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$2.16 and -$3.42 for the fiscal current year, implying an average EPS of -$3.05. EPS for the following year is -$1.74, with 12.0 analysts recommending between -$0.74 and -$3.01.
Revenue Estimates
12 analysts predict $64.08M in revenue for. The current quarter. It ranges from a high estimate of $76.6M to a low estimate of $55.19M. As of. The current estimate, Syndax Pharmaceuticals Inc’s year-ago sales were $7.68MFor the next quarter, 12 analysts are estimating revenue of $70.79M. There is a high estimate of $81.46M for the next quarter, whereas the lowest estimate is $61M.
A total of 12 analysts have provided revenue estimates for SNDX’s current fiscal year. The highest revenue estimate was $180.5M, while the lowest revenue estimate was $159.06M, resulting in an average revenue estimate of $167.95M. In the same quarter a year ago, actual revenue was $23.68MBased on 12 analysts’ estimates, the company’s revenue will be $369.27M in the next fiscal year. The high estimate is $452.87M and the low estimate is $280.25M.
